Fedratinib Hydrochloride Patent Expiration
Fedratinib Hydrochloride is Used for treating primary or secondary myelofibrosis in adult patients, monitoring thiamine levels, and administering thiamine or a thiamine equivalent. It was first introduced by Bristol-Myers Squibb Co
Fedratinib Hydrochloride Patents
Given below is the list of patents protecting Fedratinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Inrebic | US11400092 | Methods of treating myeloproliferative disorders | Sep 24, 2039 | Bristol-myers |
| Inrebic | US10391094 | Compositions and methods for treating myelofibrosis | Jun 04, 2032 | Bristol-myers |
| Inrebic | US7528143 | Bi-aryl meta-pyrimidine inhibitors of kinases | Nov 16, 2031 | Bristol-myers |
| Inrebic | US8138199 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | Jun 30, 2028 | Bristol-myers |
| Inrebic | US7825246 | Bi-aryl meta-pyrimidine inhibitors of kinases | Dec 16, 2026 | Bristol-myers |
Fedratinib Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List